6-benzylthioinosine

**6-benzylthioinosine** (often referenced as NBMPR or 6BT) is a **purine nucleoside analog** noted for several pharmacological properties: - It acts as a **selective inhibitor of human equilibrative nucleoside transporter 1 (hENT1)**, blocking adenosine and nucleoside reuptake in cells[4][5][10]. - It has demonstrated the ability to **induce differentiation and cell death in some myeloid leukemia cell lines**, specifically promoting monocytic differentiation and cell cycle arrest in acute myelogenous leukemia models, with low toxicity in non-malignant cells[3][9]. - In *Toxoplasma gondii*, it functions as a **subversive substrate for the parasite's adenosine kinase** (unlike with the human enzyme), leading to selective toxicity against the parasite and showing potential for use as an **anti-toxoplasma agent**[1][7]. - The mechanism of action for anti-leukemia effects is associated with **ENT1 inhibition** and possibly **ATP depletion**, whereas the anti-parasitic action involves it being a substrate for *T. gondii* adenosine kinase. - Structurally, analogues and derivatives have been explored for increased potency and selectivity as anti-infective or anti-cancer agents[1][7]. - Also known as NBMPR, this compound is an important **biochemical tool** for studying nucleoside transporter biology in various tissues[5][10].

Other names

6-benzylthioinosineNBMPRnitrobenzylthioinosineS-(4-nitrobenzyl)-6-thioinosine6-(p-nitrobenzylthio)inosineS6-(4-nitrylbenzyl)thioinosine6-((4-nitrobenzyl)thio)-9-β-D-ribofuranosylpurine